SARS-CoV-2 Spike S1 anticorps (RBD)

Details for Product anti-SARS-CoV-2 Spike S1 Antibody No. ABIN6952546
Antigène
  • E2
  • Surface Glycoprotein
  • S
Épitope
RBD
20
12
Reactivité
SARS Coronavirus (SARS-CoV), SARS Coronavirus-2 (SARS-CoV-2)
34
3
Hôte
Human
25
8
1
Type d'anticorp
Recombinant Antibody
Clonalité (Clone)
Monoclonal ()
Conjugué
Cet anticorp SARS-CoV-2 Spike S1 est non-conjugé
5
4
1
1
Application
Crystallization (Crys), ELISA, Neutralization (Neut), Surface Plasmon Resonance (SPR)
34
17
15
3
2
2
2
2
2
1
1
Options
Fonction Recombinant monoclonal antibody CR3022 to SARS-CoV S Glycoprotein.
Immunogène The original monoclonal antibody was generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV.
Clone CR3022
Isotype IgG1 kappa
Specificité

The antibody CR3022 binds the amino acids 318-510 in the S1 domain of the SARS-CoV Spike protein as well as SARS-CoV-2 (COVID-19) Spike protein. The antibody also binds to P462L-substituted S318-510 fragments of the SARS spike protein. The binding epitope is only accessible in the "open" conformation of the spike protein (Joyce et al. 2020).

While most S-protein RBD binding antibodies compete for antigen binding with ACE2, the CR3022 epitope does not overlap with the ACE2-binding site. It does thus not hinder binding of neutralizing antibodies. While CR3022 on its own exhibits only a weak neutralizing effect, it has been shown to synergize with other S-protein RBD binding antibodies to neutralize SARS-CoV. This effect still has to be confirmed in context with SARS-CoV-2 (Yuan et al. 2020).

Réactivité croisée (Details) The anti-SARS-CoV-2 antibody CR3022 was originally discovered in a SARS patient, but it was shown to be a potent binder of SARS-CoV-2 spike protein (S1).
Attributs du produit The original monoclonal antibody (CR3022) was generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV.

Several anti-SARS-CoV-2 Spike Protein (Subunit S1) antibodies based on clone CR3022 are available:
Human IgG1, IgG2, IgG3, IgA and IgM for use in neutralization assays and as serological controls
  • ABIN6952546 - Human IgG1
Rabbit IgG, mouse IgG2b and mouse IgM for detection applications, co-labelling studies and animal model research
  • ABIN6952547 - Rabbit IgG
Purification Protein A affinity purified
Antigène
Sujet Spike protein, COVID19, COVID 19, S protein, SARS-CoV S protein, S glycoprotein, E2, Peplomer protein, Spike protein S1, SARS Coronavirus, SARS-CoV-2, SARS CoV 2, 2019-nCoV
UniProt P59594
Indications d'application This antibody (CR3022) binds to both SARS-CoV and SARS-CoV-2 with high affinity. The initial characterization of the binding of this antibody was performed by ELISA and indicates potential for the development of diagnostic assays, as both virus-capture assays, or as controls in serological assays measuring immune-responses to virus exposure. Human IgG1, IgG3, IgM and IgA isotypes are available to mimic antibody responses seen in COVID19 (Amanat et al. 2020). Human IgG2 is available to assess its yet unknown role in the response to SARS-CoV-2. The original human IgG1 version of the antibody works synergistically in combination with another non-competing SARS antibody CR3014 and is a potential candidate for passive immune prophylaxis of SARS-CoV infection (Meulen et al., 2006). The original antibody (human IgG1) was also reported to bind the 2019-nCoV RBD (KD of 6.3 nM). This antibody has been attributed a potential to be developed as a therapeutic agent, alone or in combination with other neutralizing antibodies for treatment of 2019-nCoV infections (Tian et al., 2020).
Commentaires

The antibody clone CR3022 that is the basis for the recombinant SARS-CoV-2 Spike Subunit S1 RBD antibody ABIN6952546 was originally isolated from a convalescent SARS patient. This neutralizing antibody targets an epitope that is highly conserved in SARS-CoV and SARS-CoV-2. Crystallization studies of CR3022 bound to the SARS-CoV-2 spike protein have led to a structural model of its RBD epitope. The antibody can also detect SARS-CoV-2 in serological ELISAs.

Restrictions For Research Use only
Format Liquid
Concentration 1 mg/mL
Buffer PBS with 0.02 % Proclin 300.
Stock 4 °C,-20 °C
Stockage commentaire Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
Images (Fournisseur)
Image no. 1 for anti-SARS-CoV-2 Spike S1 (RBD) antibody (ABIN6952546) Binding curve of anti-COVID-19 & SARS-CoV S glycoprotein antibody CR3022 to SARS-CoV-...
Image no. 2 for anti-SARS-CoV-2 Spike S1 (RBD) antibody (ABIN6952546) Binding curve of anti-COVID-19 & SARS-CoV S glycoprotein antibody CR3022 (ABIN6952546...
Image no. 3 for anti-SARS-CoV-2 Spike S1 (RBD) antibody (ABIN6952546) Binding curve of anti-COVID-19 & SARS-CoV S glycoprotein antibody CR3022 (ABIN6952546...
Produit citée dans: Tian, Li, Huang, Xia, Lu, Shi, Lu, Jiang, Yang, Wu, Ying: "Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody." dans: Emerging microbes & infections, Vol. 9, Issue 1, pp. 382-385, 2020 (PubMed).

Amanat, Stadlbauer, Strohmeier, Nguyen, Chromikova, McMahon, Jiang, Asthagiri-Arunkumar, Jurczyszak, Polanco, Bermudez-Gonzalez, Kleiner, Aydillo, Miorin, Fierer, Amarilis Lugo, Milunka Kojic, Stoever, Liu, Cunningham-Rundles, Felgner, Caplivski, Garcia-S: "A serological assay to detect SARS-CoV-2 seroconversion in humans" dans: bioRxiv, 2020

Amanat, Stadlbauer, Strohmeier, Nguyen, Chromikova, McMahon, Jiang, Asthagiri-Arunkumar, Jurczyszak, Polanco, Bermudez-Gonzalez, Kleiner, Aydillo, Miorin, Fierer, Amarilis Lugo, Milunka Kojic, Stoever, Liu, Cunningham-Rundles, Felgner, Caplivski, Garcia-S: "A serological assay to detect SARS-CoV-2 seroconversion in humans" dans: bioRxiv, 2020

Xiaolong Tian, Cheng Li, Ailing Huang, Shuai Xia, Sicong Lu, Zhengli Shi, Lu Lu, Shibo Jiang, Zhenlin Yang, Yanling Wu, Tianlei Ying: "Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody." dans: bioRxiv, 2020

Stadlbauer, Amanat, Chromikova, Jiang, Strohmeier, Arunkumar, Tan, Bhavsar, Capuano, Kirkpatrick, Meade, Brito, Teo, McMahon, Simon, Krammer: "SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup." dans: Current protocols in microbiology, Vol. 57, Issue 1, pp. e100, 2020 (PubMed).

Yuan, Wu, Zhu, Lee, So, Lv, Mok, Wilson: "A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV." dans: Science (New York, N.Y.), 2020 (PubMed).

Pinto, Park, Beltramello, Walls, Tortorici, Bianchi, Jaconi, Culap, Zatta, De Marco, Peter, Guarino, Spreafico, Cameroni, Case, Chen, Havenar-Daughton, Snell, Telenti, Virgin, Lanzavecchia, Diamond et al.: "Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody." dans: Nature, 2020 (PubMed).

ter Meulen, van den Brink, Poon, Marissen, Leung, Cox, Cheung, Bakker, Bogaards, van Deventer, Preiser, Doerr, Chow, de Kruif, Peiris, Goudsmit: "Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants." dans: PLoS medicine, Vol. 3, Issue 7, pp. e237, 2007 (PubMed).

Avez-vous cherché autre chose?